// App-Quantinova.ai

P067 : GNbAC1 Shows Efficacy on MRI Measures of Neurodegeneration in Relapsing-Remitting MS Patients over 48 Weeks

Researchers

Presenter

  • Frederik Barkhof

Principal Investigators

  • Hans-Peter Hartung

  • Tobias Derfuss

  • Bruce AC Cree

  • Maria Pia Sormani

  • Hans-Martin Schneble

  • Robert L Glanzman

  • Ms. Estelle Lambert

  • Krzysztof W. Selmaj

Medical Centers

  • Vrije Universiteit Medical Centre, Amsterdam, Netherlands; UCL Institutes of Neurology and Healthcare Engineering, London, United Kingdom

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • University Hospital Basel, Basel, Switzerland

  • University of California, San Francisco, San Francisco, CA; University of California San Francisco Medical Center, San Francisco, CA

  • University of Genoa, Genoa, Italy, Francois Curtain, M.D., GeNeuro S.A., Plans les Ouates, Switzerland

  • Servier Research Institute, Munich, Germany

  • GeNeuro, Geneva, Switzerland

  • Servier, Suresnes, France

  • 12Medical University of Łódź Poland

Locations

  • United Kingdom

  • Germany

  • Switzerland

  • United States

  • France

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Temelimab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved